
5.1.2e @minvws.nl] To: From: 5.1.2e Sent: Sat 12/19/2020 9:53:01 PM Subject: RE: ECDC RT Report 17 December 2020 - Threat Assessement UK Variant Received: Sat 12/19/2020 9:53:04 PM Dearest One of the recommendations of the threat assessment sets out the need to "notify new SARS-CoV-2 variants of potential concern through the EWRS." So far UK and South Africa. Best wishes 5.1.2e) < 5.1.2e @minvws.nl> From: Sent: Saturday, December 19, 2020 10:31 PM 5.1.2e (SANTE) < 5.1.2e @ec.europa.eu> Subject: RE: ECDC RT Report 17 December 2020 - Threat Assessement UK Variant Thank you 5.1.20 We also received this document. Best regards, Van: @ec.europa.eu> Verzonden: zaterdag 19 december 2020 22:29) < 5.1.2e @minvws.nl> 5.1.2e @minvws.nl>; @ec.europa.eu>; 5.1.2e . < @ec.europa.eu> Onderwerp: FW: ECDC RT Report 17 December 2020 - Threat Assessement UK Variant Dearest I am sharing with you this draft assessment. As mentioned below, the variant could be more transmissible, but other factors could also explain recent trends in South England including social and behavioural drivers. Best wishes, From: (SANTE) < @ec.europa.eu> Sent: Saturday, December 19, 2020 8:26 PM To: (SANTE) < @ec.europa.eu> 5.1.2e Cc: (SANTE) < @ec.europa.eu> Subject: FW: ECDC RT Report 17 December 2020 - Threat Assessement UK Variant Dear 5.1.2e Find attached the draft threat assessment brief on UK (South England) SARS-CoV2 variant. Work in progress - Still being updated and publication moved forward to tomorrow (see below). Conclusions (based on limited available evidence): Could be more transmissible, but other factors could also explain recent trends in South England (as also mentioned by Prof. Piot at Thursday's scientific advice platform meeting who referred to social and behavioural drivers). Impact on diagnostic test: limited - only for one not commonly used assay Impact on severity of disease: strain seems not associated with increased severity (caveat: most cases reported so far in <60 year old) Impact on reinfection: possible, but too early to say (but likely to observe some reduction in neutralisation by antibodies)

Impact on vaccine effectiveness: unknown at this stage - the new virus variant displays several mutations

in the spike protein including in the receptor binding site. Antigenic characterisation ongoing, results in coming weeks. Reflects the need for close monitoring of field effectiveness.





Dear colleague,

We are pleased to share with you the ECDC Round Table Report. This report summarizes the daily roundtable discussion and provides update on threats detected and monitored by Epidemic Intelligence. This report contains information that might be sensitive or under verification. Its distribution is restricted to intended users only.

For further distribution, translation or copy of contents please contact support@ecdc.europa.eu.

Best regards, 5.1.2e On behalf of ECDC 24/7 duty team

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.